Genetix Biotherapeutics operates as a biotechnology company that develops genetic therapies for patients with severe rare diseases. The company offers food and drug administration (FDA)-approved genetic therapies that aim to treat the underlying causes of sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. It primarily serves the healthcare sector, focusing on patients and families affected by these rare genetic conditions. Genetix Biotherapeutics was formerly known as Bluebird Bio. It was founded in 1992 and is based in Somerville, Massachusetts.

Lumos Pharma operates as a clinical-stage biopharmaceutical company developing therapeutics for rare diseases within the biopharmaceutical industry. The company is working on new therapies for conditions with a clear pathophysiology. Lumos Pharma's lead product candidate, LUM-201, is an oral therapeutic in clinical development for Pediatric Growth Hormone Deficiency (PGHD), which, if approved, would be an alternative to current injectable treatments. It was founded in 1999 and is based in Austin, Texas.

AAVLife, registered in Paris, is a privately held company dedicated to advancing gene therapy for rare diseases. AAVLife's lead indication is for Friedreich's Ataxia Cardiomyopathy. Its program is based on the successful use of a gene-therapy approach in a mouse model developed to mimic the gene defect and cardiac symptoms of Friedreich's Ataxia. The approach made use of an adeno-associated virus (AAV) to introduce a normal gene into cardiac tissue. The therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure.

Renova Therapeutics is a biopharmaceutical company focused on developing gene and peptide therapies within the cardiovascular and metabolic disease sectors. The company's main offerings include investigational gene therapies designed to treat conditions such as congestive heart failure and type 2 diabetes. Renova Therapeutics primarily targets the healthcare industry with its therapeutic solutions. It was founded in 2009 and is based in Carlsbad, California.

Spur Therapeutics focuses on developing gene therapies for chronic conditions. It is advancing from rare disease treatments, such as Gaucher disease, to broader applications, including Parkinson's, dementia, and cardiovascular diseases. It was formerly known as Freeline Therapeutics. It was founded in 2015 and is based in Stevenage, United Kingdom. In February 2024, Spur Therapeutics was acquired by Syncona at a valuation of $28.3M.

StrideBio is a gene therapy company that develops genetic medicines for life-threatening diseases. The company's main offerings include the development of adeno-associated virus (AAV) vector-based therapies that address limitations of first-generation gene therapies, such as evasion of neutralizing antibodies and enhanced tissue targeting for conditions like monogenic rare diseases. It was founded in 2015 and is based in Research Triangle Park, North Carolina.